Drug Trial Radar · NCT05069870
A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Oct 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
42
Actual
Start
Jun 7, 2021
Primary completion
Nov 2021
Study completion Nov 2021
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a three-part, single-center, open-label phase I clinical study to characterize the DDIs potential of SKLB1028 with Itraconazole, Gemfibrozil or Rifampicin in healthy subjects. This study also aims to evaluate the safety and tolerability of SKLB1028 in the presence of Itraconazole, Gemfibrozil or Rifampicin.
Conditions
- Healthy Subjects
Interventions
SKLB1028Drug
SKLB1028, capsule, oral
ItraconazoleDrug
Itraconazole, capsule, oral
GemfibrozilDrug
Gemfibrozil, capsule, oral
RifampicinDrug
Rifampicin, capsule, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum concentration (Cmax) of SKLB1028Time frame: Up to 22 days
- Area under the concentration-time curve (AUC) from 0 to the last measurable concentration (AUC0-t) of SKLB1028Time frame: Up to 22 days
- AUC extrapolated to infinity (AUCinf) of SKLB1028Time frame: Up to 22 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.